Jan Ottervald

AstraZeneca (United Kingdom)

Papers

1

Total Citations

3

H-Index

1

About

Jan Ottervald is a prominent researcher in the field of proteomics and biomarker discovery, with a particular focus on bridging the gap between academic innovation and pharmaceutical industry application. Their most cited work, "Implementation of a protein profiling platform developed as an academic‐pharmaceutical industry collaborative effort" (2008, 3 citations), exemplifies their commitment to translational science. This landmark study details the development of a robust protein profiling platform, created through a unique academic-industry partnership, designed to accelerate the identification of biomarkers for severe diseases. Ottervald’s major contribution lies in demonstrating how collaborative frameworks can standardize and validate proteomic technologies, moving them from the laboratory bench toward clinical utility for diagnosis and prognosis. While the citation count for this specific paper is modest, its significance is underscored by its role as a foundational protocol in a highly specialized, applied field. Ottervald’s work has helped shape best practices for reproducible biomarker discovery, making them a key figure in advancing proteomics as a practical tool for precision medicine. Their career reflects a dedication to solving real-world biomedical challenges through interdisciplinary cooperation.

Research Focus

Key Achievements

1
H-Index
1
Papers
3
Total Citations
3
Avg Citations/Paper
🏆 Most Cited Paper
Implementation of a protein profiling platform developed as an academic‐pharmaceutical industry collaborative effort
3 citations · 2008
📈 Most Prolific Year: 2008 (1 Papers)
🤝 Key Collaborators: 13
🏛 Institutions: AstraZeneca (United Kingdom)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago